Kangmei Pharmaceutical Co Ltd (600518) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kangmei Pharmaceutical Co Ltd (600518) has a cash flow conversion efficiency ratio of 0.030x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥219.96 Million ≈ $32.19 Million USD) by net assets (CN¥7.22 Billion ≈ $1.06 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kangmei Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Kangmei Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Kangmei Pharmaceutical Co Ltd (600518) financial obligations for a breakdown of total debt and financial obligations.
Kangmei Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kangmei Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shikun & Binui
TA:SKBN
|
-0.080x |
|
Enaex S.A
SN:ENAEX
|
0.103x |
|
GQG Partners Inc
AU:GQG
|
0.564x |
|
First Interstate BancSystem Inc
NASDAQ:FIBK
|
0.020x |
|
QL Resources Bhd
KLSE:7084
|
0.054x |
|
COFCO Capital Holdings Co Ltd
SHE:002423
|
0.249x |
|
Tian Di Science & Technology Co Ltd
SHG:600582
|
0.005x |
|
Viohalco S.A
BR:VIO
|
0.050x |
Annual Cash Flow Conversion Efficiency for Kangmei Pharmaceutical Co Ltd (1999–2024)
The table below shows the annual cash flow conversion efficiency of Kangmei Pharmaceutical Co Ltd from 1999 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Kangmei Pharmaceutical Co Ltd worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥7.21 Billion ≈ $1.05 Billion |
CN¥-427.63 Million ≈ $-62.58 Million |
-0.059x | -32.28% |
| 2023-12-31 | CN¥7.08 Billion ≈ $1.04 Billion |
CN¥-317.52 Million ≈ $-46.46 Million |
-0.045x | +58.58% |
| 2022-12-31 | CN¥6.93 Billion ≈ $1.01 Billion |
CN¥-749.96 Million ≈ $-109.74 Million |
-0.108x | -603.84% |
| 2021-12-31 | CN¥9.97 Billion ≈ $1.46 Billion |
CN¥214.21 Million ≈ $31.34 Million |
0.021x | +121.69% |
| 2020-12-31 | CN¥-10.41 Billion ≈ $-1.52 Billion |
CN¥1.03 Billion ≈ $150.93 Million |
-0.099x | -171.00% |
| 2019-12-31 | CN¥20.65 Billion ≈ $3.02 Billion |
CN¥2.88 Billion ≈ $421.73 Million |
0.140x | +1092.59% |
| 2018-12-31 | CN¥26.12 Billion ≈ $3.82 Billion |
CN¥305.62 Million ≈ $44.72 Million |
0.012x | +106.89% |
| 2017-12-31 | CN¥28.52 Billion ≈ $4.17 Billion |
CN¥-4.84 Billion ≈ $-708.25 Million |
-0.170x | -411.09% |
| 2016-12-31 | CN¥29.38 Billion ≈ $4.30 Billion |
CN¥1.60 Billion ≈ $234.60 Million |
0.055x | +101.99% |
| 2015-12-31 | CN¥18.84 Billion ≈ $2.76 Billion |
CN¥508.86 Million ≈ $74.46 Million |
0.027x | -60.11% |
| 2014-12-31 | CN¥16.72 Billion ≈ $2.45 Billion |
CN¥1.13 Billion ≈ $165.68 Million |
0.068x | -51.33% |
| 2013-12-31 | CN¥12.03 Billion ≈ $1.76 Billion |
CN¥1.67 Billion ≈ $244.96 Million |
0.139x | +46.04% |
| 2012-12-31 | CN¥10.58 Billion ≈ $1.55 Billion |
CN¥1.01 Billion ≈ $147.55 Million |
0.095x | +53.26% |
| 2011-12-31 | CN¥9.25 Billion ≈ $1.35 Billion |
CN¥574.96 Million ≈ $84.14 Million |
0.062x | -54.24% |
| 2010-12-31 | CN¥4.93 Billion ≈ $720.79 Million |
CN¥669.19 Million ≈ $97.92 Million |
0.136x | +385.79% |
| 2009-12-31 | CN¥4.27 Billion ≈ $625.11 Million |
CN¥119.47 Million ≈ $17.48 Million |
0.028x | +2604.86% |
| 2008-12-31 | CN¥2.92 Billion ≈ $426.72 Million |
CN¥3.02 Million ≈ $441.19K |
0.001x | -98.52% |
| 2007-12-31 | CN¥2.32 Billion ≈ $339.36 Million |
CN¥162.55 Million ≈ $23.79 Million |
0.070x | +18.58% |
| 2006-12-31 | CN¥1.16 Billion ≈ $169.13 Million |
CN¥68.32 Million ≈ $10.00 Million |
0.059x | -74.53% |
| 2005-12-31 | CN¥573.59 Million ≈ $83.93 Million |
CN¥133.13 Million ≈ $19.48 Million |
0.232x | +51.30% |
| 2004-12-31 | CN¥511.88 Million ≈ $74.90 Million |
CN¥78.52 Million ≈ $11.49 Million |
0.153x | -13.01% |
| 2003-12-31 | CN¥442.44 Million ≈ $64.74 Million |
CN¥78.02 Million ≈ $11.42 Million |
0.176x | +29.03% |
| 2002-12-31 | CN¥391.23 Million ≈ $57.25 Million |
CN¥53.47 Million ≈ $7.82 Million |
0.137x | +218.04% |
| 2001-12-31 | CN¥365.10 Million ≈ $53.43 Million |
CN¥15.69 Million ≈ $2.30 Million |
0.043x | -55.15% |
| 2000-12-31 | CN¥103.96 Million ≈ $15.21 Million |
CN¥9.96 Million ≈ $1.46 Million |
0.096x | -64.81% |
| 1999-12-31 | CN¥111.12 Million ≈ $16.26 Million |
CN¥30.25 Million ≈ $4.43 Million |
0.272x | -- |
About Kangmei Pharmaceutical Co Ltd
Kangmei Pharmaceutical Co., Ltd. produces and sells Chinese herbal medicines in China. The company offers Chinese patent medicines, chemical medicines, and health food products. In addition, it engages in the operation of Chinese medicinal materials markets; production and sale of medical devices; and operation of pharmaceutical logistics system. The company provides its products through medical … Read more